title: Intrabronchial instillation of amphotericin B lipid complex: a case report.
abstract: OBJECTIVE
  We sought to present our results of topical intrabronchial installation of amphotericin B lipid complex (AmpB lipid).
  
  
  METHODS
  A deposit of fungal material was observed in a bilateral lung transplant recipient who experienced stenosis of the left anastomosis and have been fitted with a double endobronchial prosthesis. The deposit was adherent to the prosthetic material, causing marked local laceration, risk of perforation, and exacerbation of the bronchial stenosis. Upon cultivation of a bronchial aspirate (BAS), we isolated Aspergillus fumigatus, Scedosporium prolificans, and Candida glabrata. Systemic antifungal treatment was begun with oral voriconazole (200 mg every 12 hours) and inhaled AmpB lipid (25 mg once daily). The fungal deposit on the prosthetic material was treated by topical instillation of a solution of 25 mg AmpB lipid before and after each therapeutic fibrobronchoscopy (FB), which was performed weekly at 5 consecutive examinations. Tolerance was excellent.
  
  
  RESULTS
  The improvement obtained after the procedure made it possible to withdraw one of the displaced prostheses. Subsequent cultivation for the fungi found in the BAS was persistently negative over a follow-up of 2 years.
  
  
  CONCLUSIONS
  Topical intrabronchial instillation of AmpB lipid has proven effective and well tolerated for the treatment of localized fungal colonies. This use could be extended by protocol to FB in the early postoperative period after lung transplantation for antifungal prophylaxis.
authors.affiliation: U Trasplante Pulmonar, Hospital Clínico, Valencia, Spain. pila1460@separ.es
authors.forename: P
authors.initials: P
authors.lastname: Morales
authors.forename: G
authors.initials: G
authors.lastname: Galán
authors.forename: E
authors.initials: E
authors.lastname: Sanmartín
authors.forename: E
authors.initials: E
authors.lastname: Monte
authors.forename: V
authors.initials: V
authors.lastname: Tarrazona
authors.forename: M
authors.initials: M
authors.lastname: Santos
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy; D001232:Aspergillus fumigatus / Q000187:drug effects / Q000302:isolation & purification; D001980:Bronchi; D041221:Candida glabrata / Q000187:drug effects / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy; D003550:Cystic Fibrosis / Q000601:surgery; D005500:Follow-Up Studies; D006801:Humans; D007322:Instillation, Drug; D016040:Lung Transplantation / Q000009:adverse effects*; D008297:Male; D008271:Mycetoma / Q000188:drug therapy; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology; D021681:Scedosporium / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B